Expression Vector Enhances Protein Yield via Regulatory Elements
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The high cost of manufacturing recombinant biologics, particularly those produced using mammalian expression systems, remains a significant concern due to low expression levels and high production costs, despite advances in improving gene expression and fermentation conditions.
Innovation Solution
A novel expression vector combining a CMV immediate early promoter, Adenovirus Tripartite Leader element, hybrid intron, Adenoviral Virus Associated RNA genes I & II, and bovine growth hormone polyadenylation sequence, which synergistically enhances protein expression in mammalian host cells, achieving 80-100% higher expression levels of recombinant proteins like EPO compared to existing vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mammalian expression systems are used to produce recombinant biologics, then protein functionality and glycosylation are improved, but manufacturing cost increases and productivity decreases
Solution Approach 1:
The patent modifies multiple parameters of the expression system simultaneously: promoter strength (CMV immediate early promoter), RNA processing elements (tripartite leader sequence, 5' UTR, 3' UTR), polyadenylation signals (BGH poly A), and selection markers (DHFR). These parameter changes collectively enhance expression efficiency while maintaining protein quality, resolving the contradiction between functionality and productivity
Solution Approach 2:
The patent combines multiple viral and eukaryotic regulatory elements into a single integrated expression cassette: CMV promoter + tripartite leader sequence + 5' UTR + coding sequence + 3' UTR + BGH poly A signal. This merged construct synergistically enhances transcription and translation efficiency, achieving high productivity while maintaining mammalian expression system advantages
2Quantity of substance
If existing expression vectors are used, then basic protein expression is achieved, but expression levels remain low leading to high production costs
Solution Approach 1:
The patent optimizes multiple expression parameters beyond simple promoter selection: uses CMV immediate early promoter for high transcriptional activity, incorporates tripartite leader sequence for enhanced translation initiation, adds specific 5' and 3' UTR sequences for mRNA stability and efficiency, and includes BGH poly A signal for proper transcript processing. These parameter changes collectively achieve 5-10 fold higher expression levels, directly reducing production costs
Solution Approach 2:
The expression vector construct comprises a composite of multiple regulatory elements from different viral and eukaryotic sources: CMV promoter (viral), tripartite leader sequence (adenoviral), BGH poly A signal (viral). This composite construct synergistically enhances expression, achieving high protein yields that reduce manufacturing costs
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
A process for high expression of protein of interest using an expression vector. The process comprises at least the following regulatory elements: a) a CMV promoter, or its functional variants, b) an intron, c) TPL or its functional variants, d) VA genes or functional variants, and e) a bovine growth hormone polyadenylation sequence or functional variants.